Sulfaphenazole: A Benchmark CYP2C9 Inhibitor for Vascular and Drug Metabolism Research

Executive Summary: Sulfaphenazole (CAS No. 526-08-9) is a highly selective, competitive inhibitor of cytochrome P450 enzymes CYP2C6 and CYP2C9, exhibiting an IC₅₀ of 0.63 μM for CYP2C9 under standard in vitro conditions (Elmi et al., 2008). It restores endothelium-dependent vasodilation in diabetic mice by reducing CYP2C-mediated oxidative stress and enhancing nitric oxide (NO) bioavailability. Sulfaphenazole displays potent antibacterial activity against Mycobacterium tuberculosis, including extensively drug-resistant strains, by inhibiting bacterial dihydropteroate synthase (DHPS). It is characterized by low cytotoxicity (IC₅₀ >64 μg/mL on Vero cells) and high solubility in DMSO (≥13.15 mg/mL). APExBIO provides Sulfaphenazole (SKU: C4131) with validated batch consistency and stability for research applications requiring precise CYP2C9 inhibition (product page).

Biological Rationale

Sulfaphenazole is a sulfonamide compound engineered for selective inhibition of cytochrome P450 2C9 (CYP2C9) and 2C6 isoenzymes. Cytochrome P450 enzymes catalyze oxidative biotransformation of xenobiotics and endogenous substrates, impacting drug metabolism and vascular homeostasis (Elmi et al., 2008). In diabetes and cardiovascular disease, CYP2C9-mediated superoxide production decreases NO bioavailability, contributing to endothelial dysfunction. Inhibition of CYP2C9 suppresses ROS generation and restores vasodilation. Sulfaphenazole also targets bacterial dihydropteroate synthase, disrupting folic acid synthesis and exerting selective antibacterial effects, notably against Mycobacterium tuberculosis, including XDR-TB strains. The compound’s high selectivity and low off-target activity support its widespread use in drug metabolism modulation, vascular function research, and antibacterial studies (see review—this article provides quantitative pharmacokinetic context and updates mechanistic insight).

Mechanism of Action of Sulfaphenazole

Sulfaphenazole competitively inhibits CYP2C9 and CYP2C6 by binding to the active site of the heme-containing monooxygenase, blocking substrate access and preventing electron transfer required for oxidation. This suppression of CYP2C-mediated redox cycling reduces superoxide and hydrogen peroxide generation during arachidonic acid metabolism (Elmi et al., 2008). In bacterial systems, Sulfaphenazole interferes with DHPS, halting the condensation of para-aminobenzoic acid (PABA) with dihydropteridine pyrophosphate and ultimately blocking folate biosynthesis. The dual mechanism underpins its utility as both an anti-tuberculosis agent and a research tool for vascular and pharmacogenetic studies. Solubility characteristics (insoluble in water, soluble in DMSO ≥13.15 mg/mL, ethanol ≥9.92 mg/mL with ultrasonic assistance) facilitate formulation across multiple in vitro and in vivo platforms (APExBIO).

Evidence & Benchmarks

• Sulfaphenazole restores endothelium-dependent vasodilation in db/db diabetic mice, with daily intraperitoneal injections (5.13 mg/kg) for 8 weeks reversing impaired acetylcholine-mediated relaxation (Elmi et al., 2008).
• Reduces plasma 8-isoprostane (oxidative stress marker) and increases plasma NO₂^- (NO bioavailability) in diabetic models, without altering plasma glucose levels (Elmi et al., 2008).
• Inhibits CYP2C9 with an in vitro IC₅₀ of 0.63 μM, supporting its role as a gold-standard competitive CYP2C9 inhibitor (article—this extends on specificity and assay reproducibility).
• Demonstrates significant anti-tubercular activity (MIC 5–30 μg/mL) against clinical and XDR-TB strains via DHPS inhibition (review).
• Displays low cytotoxicity in Vero cell assays (IC₅₀ >64 μg/mL), ensuring suitability for cellular and animal studies (APExBIO).
• Solubility profile: insoluble in water, but soluble in DMSO (≥13.15 mg/mL) and ethanol (≥9.92 mg/mL, ultrasonic), enabling flexible assay design (APExBIO).
• Used in vascular injury and wound healing models to reduce inflammation, fibrosis, and promote macrophage bactericidal activity (article—this article updates translational and tissue repair applications).

Applications, Limits & Misconceptions

Sulfaphenazole is widely adopted in:

• Drug metabolism modulation: Dissects CYP2C9/2C6-mediated pathways critical to adverse drug reaction studies and pharmacogenetics.
• Vascular endothelial function research: Models diabetic vascular dysfunction, ischemia-reperfusion injury, and oxidative stress reduction (see prior article—this work clarifies quantifiable effects on NO bioavailability and ROS suppression).
• Anti-tuberculosis research: Inhibits DHPS in M. tuberculosis, including XDR-TB strains, for preclinical antibacterial screening.
• Tissue repair studies: Enhances wound healing by reducing inflammation and promoting macrophage function.

Common Pitfalls or Misconceptions

• Sulfaphenazole is not effective as a broad-spectrum antibiotic; its antibacterial effects are specific to DHPS-expressing species and are not generalizable to all bacteria.
• It does not inhibit all cytochrome P450 isoforms; selectivity is primarily for CYP2C9 and CYP2C6, with minimal activity against CYP3A4 or CYP2D6.
• Not suitable for long-term aqueous solution storage; stability is optimal at -20°C and for short-term applications (APExBIO).
• Does not normalize plasma glucose in diabetic models; its effects are limited to vascular and oxidative stress pathways (Elmi et al., 2008).
• Not intended for clinical therapeutic use; for research applications only.

Workflow Integration & Parameters

Solubility & Preparation: Dissolve Sulfaphenazole in DMSO (≥13.15 mg/mL) or ethanol (≥9.92 mg/mL, ultrasonic) for stock solutions. Store at -20°C; use fresh solutions for in vitro assays and animal injections.
Recommended concentrations: 0.5–11.5 μM for CYP inhibition assays; 5–30 μg/mL in anti-TB cell culture; 1–10 μM for cell-based function studies.
In vivo dosing: 5.13 mg/kg i.p. daily (mouse models) to restore vascular function and model diabetic endothelial dysfunction (Elmi et al., 2008).
Safety: Low cytotoxicity enables use in a wide range of preclinical settings.

For more detailed mechanistic discussion and protocol optimization, see Sulfaphenazole and Precision CYP2C9 Inhibition in Vascular Research—this article expands on concentration-dependent effects and translational workflow design.

Conclusion & Outlook

Sulfaphenazole stands as a highly validated, selective CYP2C9/2C6 inhibitor and antibacterial tool. Its ability to restore vascular endothelial function, reduce oxidative stress, and provide a model system for drug-drug interaction studies is consistently supported by peer-reviewed evidence (Elmi et al., 2008). With a favorable safety profile and robust solubility properties, APExBIO’s Sulfaphenazole (SKU: C4131) is positioned as a gold standard for researchers in pharmacogenetics, adverse drug reaction modeling, and vascular biology. Future work should focus on expanding its application in precision medicine and high-throughput screening for CYP2C9-related drug interactions.